1. Home
  2. HAFC vs DSGN Comparison

HAFC vs DSGN Comparison

Compare HAFC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

HOLD

Current Price

$32.49

Market Cap

972.5M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$14.39

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAFC
DSGN
Founded
1982
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
972.5M
853.8M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
HAFC
DSGN
Price
$32.49
$14.39
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
$32.17
$15.25
AVG Volume (30 Days)
255.0K
437.9K
Earning Date
04-21-2026
04-28-2026
Dividend Yield
3.75%
N/A
EPS Growth
22.44
N/A
EPS
1.54
N/A
Revenue
$270,165,000.00
N/A
Revenue This Year
$18.65
N/A
Revenue Next Year
$7.28
N/A
P/E Ratio
$20.94
N/A
Revenue Growth
15.28
N/A
52 Week Low
$22.85
$4.68
52 Week High
$33.50
$17.25

Technical Indicators

Market Signals
Indicator
HAFC
DSGN
Relative Strength Index (RSI) 55.39 64.32
Support Level $31.45 $9.78
Resistance Level $32.70 $17.10
Average True Range (ATR) 0.45 0.70
MACD 0.00 0.25
Stochastic Oscillator 77.17 88.82

Price Performance

Historical Comparison
HAFC
DSGN

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: